A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism.

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms Du Lac
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2010 Planned end date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 09 Dec 2010 Planned initiation date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 24 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top